COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

PsoVac: Educational Needs re Vaccines for Biologic Patients With Psoriasis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT04513847
Recruitment Status : Completed
First Posted : August 14, 2020
Last Update Posted : October 8, 2020
Information provided by (Responsible Party):
Ronald Vender MD FRCPC, Dermatrials Research

Brief Summary:
To determine if there is a need for further education on vaccines with psoriasis patients who are on a biologic. In regards to the COVID-19, it is important that psoriasis patients - whether on a biologic or not - understand whether they can have certain vaccines. That will depend on the type of vaccine that becomes available.

Condition or disease
Psoriasis Covid19

Layout table for study information
Study Type : Observational
Actual Enrollment : 661 participants
Observational Model: Case-Control
Time Perspective: Other
Official Title: PsoVac: A Psoriatic Patient-based Survey on the Understanding of the Use of Vaccines While on Biologics During the Covid-19 Pandemic
Actual Study Start Date : August 13, 2020
Actual Primary Completion Date : September 13, 2020
Actual Study Completion Date : October 6, 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Psoriasis

Psoriasis patients treated with non-biologic
Psoriasis patients treated with biologic

Primary Outcome Measures :
  1. Percentage of patients not understanding the interaction of vaccines and their biologic, assessed with voluntary survey. [ Time Frame: Data will be collected over a span of 3 months ]
    Assessment is based upon survey responses. By answering multiple questions we will determine if more education is needed based on the answers.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Dermatology Clinic

Inclusion Criteria:

  • psoriasis patient

Exclusion Criteria:

  • no exclusions

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT04513847

Layout table for location information
Canada, Ontario
Dermatrials Research
Hamilton, Ontario, Canada, L8N 1V6
Sponsors and Collaborators
Dermatrials Research
Layout table for additonal information
Responsible Party: Ronald Vender MD FRCPC, Associate Clinical Professor, Division of Dermatology MD FRCPC, Dermatrials Research Identifier: NCT04513847    
Other Study ID Numbers: Pso-Vac
First Posted: August 14, 2020    Key Record Dates
Last Update Posted: October 8, 2020
Last Verified: October 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Ronald Vender MD FRCPC, Dermatrials Research:
Additional relevant MeSH terms:
Layout table for MeSH terms
Skin Diseases, Papulosquamous
Skin Diseases